BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ALung Technologies Raises $10 Million in Series B Financing


2/6/2012 7:21:49 AM

PITTSBURGH--(BUSINESS WIRE)-- ALung Technologies, Inc., a leading developer of advanced respiratory products, announced today that it has closed a $10 million Series B financing round. The investment will support the continued commercialization of ALung’s flagship product, the Hemolung®Respiratory Assist System (RAS), which provides partial respiratory assistance to patients in acute respiratory failure. The device is expected to allow patients to avoid intubation and invasive mechanical ventilation in many cases.

“We recently completed a 20-patient clinical trial of the Hemolung RAS in Germany and found the results to be very encouraging,” said Peter DeComo, Chairman and CEO of ALung Technologies. The results of the trial are currently being reviewed by regulators as part of the Company’s application for European marketing clearance known as the CE mark. “Completing the clinical trial and regulatory filing for the CE mark were significant achievements for our company last year. Our ability to secure this latest financing in a period of just four months reflects the confidence of our investors in the potential of the Hemolung RAS to make a real difference in the lives of patients suffering from acute respiratory failure.”

Participants in the financing included existing shareholders, co-investors of Eagle Ventures, and Birchmere Ventures. “We continue to be very excited about ALung and the Hemolung technology,” said Gary Glausser, Partner at Birchmere Ventures, a Pittsburgh-based early-stage venture capital firm that bolstered its investment in ALung through the Series B round. “The Hemolung device is the first truly new option for patients with acute respiratory failure in many years and ALung continues to make great progress toward commercializing the product.”

About ALung Technologies, Inc.

ALung Technologies, Inc. is a Pittsburgh-based developer and manufacturer of innovative lung assist devices. ALung is commercializing the Hemolung Respiratory Assist System (RAS), a dialysis-like alternative or supplement to mechanical ventilation originally developed at the University of Pittsburgh. The Hemolung RAS removes carbon dioxide and delivers oxygen directly to the blood, allowing the patient’s lungs to rest and heal. A simple extracorporeal circuit, small venous catheter, and techniques similar to hemodialysis make the Hemolung RAS easy to use. The Hemolung RAS is currently an investigational device, and is not yet available for sale in any market.

For additional information, please visit: http://www.alung.com

This press release may contain forward-looking statements, which, if not based on historical facts, involve current assumptions and forecasts as well as risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company's control. Events that could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement for the Company’s products/services, and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

Contact:

ALung Technologies, Inc.

Scott Morley, Vice President of Marketing, +1-412-697-3370

smorley@alung.com



Read at BioSpace.com
Read at News Release
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES